Funding for this research was provided by:
Text and Data Mining valid from 2019-04-08
First Online: 8 April 2019
Change Date: 6 May 2019
Change Type: Correction
Change Details: The authors would like to correct the error in the publication of the original article. The correction detail is given below:
Compliance with Ethical Standards
: The Open Access Article Processing Charge was funded by Amgen Inc. This study was fully funded by Amgen Inc. Erenumab is co-developed in partnership with Amgen Inc. and Novartis. Jon Nilsen, PhD (Amgen Inc.) provided medical writing support for this manuscript.
: Yang Xu, Kristin Gabriel, Yi Wang, Yanchen Zhou, Osaro Eisele, Daniel D. Mikol, and Edward Lee are or were employees and stockholders of Amgen Inc. at the time of the study. Apinya Vutikullird is an employee of WCCT Global, which received research funding for this study.
: Institutional Review Boards at each center approved the study protocol. Sites maintained compliance with the Health Insurance Portability and Accountability Act or relevant regional regulations. The study was conducted in accordance with the ethical principles of the International Conference on Harmonisation Good Clinical Practice Guidelines (ICH GCP) and the Helsinki Declaration of 1975 (as revised in 2008).
: All patients provided written informed consent.